That is, an approach to improving the treatment of CDD may lie not only in restoring CDKL5 itself but in adjusting the downstream changes or in compensating for CDKL5 loss by enhancing the actions of complementary proteins (e.g., CDKL2) [72]. Here, CDKL2 is linked to craniodiaphyseal dysplasia.